Funding News - Applications for Parkinson's Disease Neuroprotection Clinical Trial (Clinical Centers) Requested

Skip secondary menu

The National Institute of Neurological Disorders and Stroke (NINDS) requests applications for clinical centers to collaborate on a large, double-blind randomized trial of two or more potential neuroprotective agents in patients early in the course of Parkinson's disease (PD).* The intent of this request for applications (RFA) is to solicit applications from qualified investigators proposing to serve as clinical centers in order to conduct a large, collaborative randomized double-blind trial testing neuroprotective agents in patients with early PD. A clinical center is an institution that is actively involved with the recruitment, evaluation, treatment, and follow-up of study participants. It will consist of a team of researchers with the neurological skills to apply diagnostic criteria for PD and criteria for study selection, and to deliver medical care to PD patients. Optimally, the team will also have experience in collaborative clinical studies. The center(s) may have agreements with other nearby institutions to recruit and treat patients for this study. APPLICATION RECEIPT DATE: November 15, 2001. For more information, potential applicants should contact Dr. Bernard Ravina, Program Director, Clinical Trials Cluster, NINDS, Neuroscience Center, 6001 Executive Boulevard, Room 2225, Bethesda, MD 20892; telephone: (301) 496-9135; fax: (301) 480-1080; e-mail: ravinab@ninds.nih.gov.

*For a more detailed description of this RFA, please visit the NIH web site at: http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-02-010.html.


This content has been adapted from the original NINDS Notes publication. For the most up-to-date funding information, please visit the Funding Opportunities section of the NINDS web site.  For the most recent information on NINDS studies, please visit the NINDS Patient Recruitment web site.